Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06025578 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
A Phase 3 study of Progressive Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 1,092
- Enrollment target
- 20
- Study locations
NCT06025578: Active Phase 3 study of Progressive Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.
NCT06025578 is a Phase 3 study of Progressive Pulmonary Fibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,092 participants, above the 549-participant average among 7 other Progressive Pulmonary Fibrosis trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06025578, a Phase 3 study of Progressive Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,092 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Primary Outcome
Cohort 1
Conditions Studied
Interventions
- DRUG BMS-986278
- DRUG BMS-986278 Placebo
Study Locations (20)
California
- Local Institution - 0336 - La Jolla
- Local Institution - 0212 - Los Angeles
- Local Institution - 0019 - Los Angeles
- Local Institution - 0535 - Newport Beach
- Local Institution - 0366 - Orange
- Local Institution - 0341 - Sacramento
- Local Institution - 0015 - San Francisco
- Local Institution - 0352 - Stanford
Florida
- Local Institution - 0195 - Brandon
- Local Institution - 0380 - Celebration
- Local Institution - 0013 - Clearwater
- Local Institution - 0396 - DeBary
Colorado
- Local Institution - 0321 - Aurora
- Local Institution - 0376 - Denver
Connecticut
- Local Institution - 0211 - New Haven
- Local Institution - 0418 - Stamford
Alabama
- Local Institution - 0046 - Birmingham
Arizona
- Local Institution - 0314 - Phoenix
Delaware
- Local Institution - 0067 - Newark
District of Columbia
- Local Institution - 0354 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,092 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2027-12-27 |
| Phase | Phase 3 |
What the registry record for NCT06025578 still lists
NCT06025578 is an interventional study that assigns participants to a tested intervention. Its 1,092 participants enrollment target places it among the larger protocols in the corpus, above the 549-participant average among 7 other Progressive Pulmonary Fibrosis trials with a reported enrollment target (99% higher).
The record links to 1 condition, with Progressive Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986278 is the first listed.
NCT06025578 names 20 study sites across 8 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06025578 about?
NCT06025578 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
What is the current status of trial NCT06025578?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,092 participants. The study started on 2023-10-25. Estimated completion is 2027-12-27.
What conditions does trial NCT06025578 study?
This clinical trial studies the following conditions: Progressive Pulmonary Fibrosis.
What interventions are being tested in trial NCT06025578?
The interventions under investigation include: BMS-986278 (DRUG), BMS-986278 Placebo (DRUG).
Who is sponsoring clinical trial NCT06025578?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06025578 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
RECRUITING · Phase 3
-
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
RECRUITING · Phase 2
-
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
RECRUITING
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI